About this trial
This prospective clinical trial aims to evaluate the efficiency, safety, and reliability of a minimally invasive graftless transcrestal sinus lifting approach with simultaneous dental implant placement in patients with edentulous posterior maxilla and limited residual bone height.
The study investigates bone formation beneath the Schneiderian membrane, implant stability, osseointegration, and long-term implant survival.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adults aged 18-80 years.
Patients with edentulous posterior maxilla.
Residual bone height approximately 4-6 mm.
Indicated for transcrestal sinus membrane elevation.
Disqualifiers
Severe systemic diseases (ASA III or above).
Uncontrolled diabetes mellitus.
Active sinus pathology.
History of radiotherapy in the head and neck region.
Trial design
Single group
Treatments tested in this trial
Graftless Transcrestal Sinus Membrane Elevation with Simultaneous Implant Placement
Procedure/SurgeryA minimally invasive transcrestal approach for sinus membrane elevation without graft material, followed by simultaneous placement of a 10 mm length and 4-4.5 mm diameter dental implant in the posterior maxilla with residual bone height of approximately 5 mm.
Treatment groups
Trial outcomes
Primary outcomes
Amount of Newly Formed Bone After Graftless Transcrestal Sinus Elevation
Radiographic assessment of the amount of newly formed bone in the elevated sinus space using CBCT.
Locations
1Map coordinates are unavailable for these locations. Locations are shown below instead.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.